Source: Mindray Medical official website.
On January 28thShenzhen Mindray Biomedical Electronics Co., Ltd. ***(abbreviated as Mindray Medical).The announcement saidIt is proposed to use 66500 million yuan of its own fundsRealize the medical device companies listed on the Science and Technology Innovation BoardShenzhen Huitai Medical Equipment Co., Ltd. ***(referred to as Huitai Medical).Acquisition of Control.
If the full acquisition plan is successfully implemented, Mindray Medical will hold a total of 2461% of the shares, becoming the largest shareholder and controlling shareholder of Huitai MedicalThe actual controllers of Huitai Medical will be changed to Li Xiting, chairman of Mindray Medical, and Xu Hang, co-founder of Mindray Medical.
According to public information, Mindray Medical is the largest medical device company in China in terms of revenue, and its monitors, anesthesia machines, blood cell analyzers and ventilators have all reached the world-class level. Huitai Medical is a leading enterprise in the cardiovascular segment in China, and is also the first domestic manufacturer in China to obtain market access for electrophysiology electrode catheters, controllable radiofrequency ablation electrode catheters, and floating temporary pacing electrode catheters and enter clinical applications, filling the domestic gap in the field of cardiac electrophysiology.
As for the follow-up plans after the acquisition, the parties to the transaction said in the disclosed announcement, "Mindray will use this to enter the cardiovascular fieldUsing its accumulation and talent reserve in the field of medical devices, it helps Huitai Medical improve its R&D capabilities; It will also combine the advantages of global marketing resources to promote the development of cardiovascular business such as Huitai Medical's electrophysiology and related consumables; At the same time, it will lay the foundation for future horizontal business expansion, enhance the comprehensive business competitiveness of Huitai Medical, and promote the development of China's medical and health industry.
* |Announcements of listed companies.
Hui Shang "full**.
Edit |Yu Hongbo.
First instance |Qi Fei.
Second instance |Liang Shuang.
Third Instance |Bao Xiaochun.